• awesomeicons6/solid/lock 100% Secure Online Payments

Anti-Methicillin-Resistant Staphylococcus Aureus [Clone NYR-MRSA]

Anti-Methicillin-Resistant Staphylococcus Aureus [Clone NYR-MRSA] (15715-GRP)

Products

Sort by arrow-down-short-wide arrow-up-short-wide
Cat #
Size
Price
Cat # Size
chevron-left chevron-right
of

Description

Methicillin-resistant Staphylococcus aureus (MRSA) survives treatment with broad-spectrum beta-lactam antibiotics including penicillin, methicillin, and cephalosporins. Previously, most MRSA infections occurred in hospitals or other health care settings, such as nursing homes and dialysis centers and were known as “health care-associated MRSA” or HA-MRSA. Older adults and people with weakened immune systems were most at risk of contracting HA-MRSA. More recently, another type of MRSA has occurred among otherwise healthy people in the wider community. This form, “community-associated MRSA”, or CA-MRSA, causes serious skin and soft tissue infections and a potentially lethal form of pneumonia.

Specifications

Manufacturer Leinco Technologies Inc
Manufacturer Cat# 15715
Formulation Lyophilized purified antibody in PBS at a concentration of 1mg/ml.
Clone 198
Target Methicillin-resistant Staphylococcus aureus (MRSA)
Applications IHC, WB
Storage This lyophilized product is stable for two years at 4°C. After reconstitution, store aliquots at -20°C.